Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Liabilities: 2009-2024

Historic Total Liabilities for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $855.2 million.

  • Ani Pharmaceuticals' Total Liabilities rose 5.34% to $902.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $902.3 million, marking a year-over-year increase of 5.34%. This contributed to the annual value of $855.2 million for FY2024, which is 91.39% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Total Liabilities is $855.2 million, which was up 91.39% from $446.8 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Total Liabilities high stood at $855.2 million for FY2024, and its period low was $265.5 million during FY2020.
  • Its 3-year average for Total Liabilities is $574.5 million, with a median of $446.8 million in 2023.
  • Data for Ani Pharmaceuticals' Total Liabilities shows a peak YoY soared of 91.39% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Total Liabilities stood at $265.5 million in 2020, then surged by 55.51% to $412.9 million in 2021, then rose by 2.10% to $421.5 million in 2022, then rose by 6.00% to $446.8 million in 2023, then spiked by 91.39% to $855.2 million in 2024.